Document Detail

Plasminogen activator inhibitor-1 is associated with impaired endothelial function in women with systemic lupus erythematosus.
MedLine Citation:
PMID:  16126968     Owner:  NLM     Status:  MEDLINE    
Endothelial function, measured noninvasively by brachial artery flow-mediated dilatation (FMD), has been shown to be impaired in patients with systemic lupus erythematosus (SLE). We hypothesized that depressed FMD in SLE patients is associated with increased levels of plasminogen activator inhibitor-1 (PAI-1), an inhibitor of fibrinolysis and regulator of vasoactivity. In this cross-sectional study of female SLE patients under the age of 55, putative markers of cardiovascular disease (CVD) such as PAI-1 were measured in addition to lupus-related disease activity (SLEDAI). The primary outcome, FMD, was measured using high-resolution ultrasound of the brachial artery gated to the R wave to determine endothelial-dependent vasomotion. Endothelial-independent vasomotion was measured in response to nitroglycerin (NMD). Seventy-six female SLE patients, mean age 38.3 +/- 9.4 years, were included. All patients demonstrated normal NMD responses, indicating that depression of FMD was related to decreased endothelial nitric oxide production. Increased PAI-1 was related to depressed FMD by univariate regression (P = 0.004). In a multivariable regression model adjusting for t-PA (tissue plasminogen activator)/PAI-1 ratio, SLEDAI, age at visit, family history of cardiovascular disease, SLE disease duration and body mass index, every 1 ng/mL increase in PAI-1 was associated with a reduction of 0.07 units FMD (P = 0.039). PAI-1 was associated with impaired endothelial dysfunction, after controlling for several potential confounders. Given the high incidence of cardiovascular disease in SLE, further investigation of the role of subclinical markers of CVD is needed.
Emily C Somers; Wendy Marder; Mariana J Kaplan; Robert D Brook; W Joseph McCune
Related Documents :
12922968 - European scleroderma study group to define disease activity criteria for systemic scler...
1550398 - Increased excretion of soluble interleukin 2 receptors and free light chain immunoglobu...
3717808 - Total lymphoid irradiation in refractory systemic lupus erythematosus.
16609348 - Vasculitis in systemic lupus erythematosus: prevalence and clinical characteristics in ...
10842758 - Childhood diabetic neuropathy: a clinical and electrophysiological study.
23674828 - Glutamate oxaloacetate transaminase: a new key in the dysregulation of glutamate in mig...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Annals of the New York Academy of Sciences     Volume:  1051     ISSN:  0077-8923     ISO Abbreviation:  Ann. N. Y. Acad. Sci.     Publication Date:  2005 Jun 
Date Detail:
Created Date:  2005-08-29     Completed Date:  2006-06-26     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  7506858     Medline TA:  Ann N Y Acad Sci     Country:  United States    
Other Details:
Languages:  eng     Pagination:  271-80     Citation Subset:  IM    
Division of Rheumatology, University of Michigan Health System, 1150 W. Medical Center Dr., 5520 MSRB 1, Ann Arbor, MI 48109-0680, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cross-Sectional Studies
Endothelium, Vascular / physiopathology*
Lupus Erythematosus, Systemic / blood,  physiopathology*
Middle Aged
Plasminogen Activator Inhibitor 1 / blood*
Tissue Plasminogen Activator / blood
Grant Support
Reg. No./Substance:
0/Plasminogen Activator Inhibitor 1; EC Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Association of rheumatoid arthritis with HLA-DR1 and HLA-DR4 in Hungary.
Next Document:  Early atherosclerosis in rheumatoid arthritis: effects of smoking on thickness of the carotid artery...